The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
New funding supports development of embodied AI foundation models, commercial deployments and integrated robotics infrastructure, only embodied AI company backed by all four major Chinese...
JINCHANG, China, June 29, 2026 /PRNewswire/ -- Recently, staff from State Grid Jinchang Power Supply Company conducted a special safety inspection on power consumption...
Infrastructure, Investment and Vietnam's Next Growth Chapter HO CHI MINH CITY, Vietnam, June 29, 2026 /PRNewswire/ -- Bloomberg Businessweek Vietnam (BBWV) will host...
